iifl-logo-icon 1

Ahlcon Parenterals India Ltd Share Price

515
(-0.19%)
Jan 21, 2015|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Ahlcon Parenterals India Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

515

Prev. Close

516

Turnover(Lac.)

151.93

Day's High

516.75

Day's Low

514.75

52 Week's High

0

52 Week's Low

0

Book Value

-172.11

Face Value

10

Mkt Cap (₹ Cr.)

370.8

P/E

0

EPS

0

Divi. Yield

0

Ahlcon Parenterals India Ltd Corporate Action

No Record Found

Ahlcon Parenterals (India) Ltd NEWS AND UPDATE

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Ahlcon Parenterals (India) Ltd SHAREHOLDING SNAPSHOT

24 Aug, 2024|09:37 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 93.26%

Foreign: 93.26%

Indian: 0.00%

Non-Promoter- 6.73%

Institutions: 0.00%

Non-Institutions: 6.73%

Custodian: 0.00%

Share Price

Ahlcon Parenterals India Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

7.2

7.2

7.2

7.2

Preference Capital

0

0

0

0

Reserves

-131.12

-123.13

-103.34

-56.31

Net Worth

-123.92

-115.93

-96.14

-49.11

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2017Mar-2016Mar-2015Mar-2014

Revenue

135.38

118.99

115.98

119.96

yoy growth (%)

13.77

2.59

-3.32

11.38

Raw materials

-46.44

-40.62

-41.17

-41.5

As % of sales

34.3

34.14

35.5

34.59

Employee costs

-24.56

-22.44

-17.67

-15.88

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2017Mar-2016Mar-2015Mar-2014

Profit before tax

-13.82

-23.77

20.88

30.06

Depreciation

-16.3

-16.12

-4.6

-3.44

Tax paid

0

5.23

-3.87

-10.55

Working capital

6.71

0.76

-24.6

19.6

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2017Mar-2016Mar-2015Mar-2014

Growth matrix (%)

Revenue growth

13.77

2.59

-3.32

11.38

Op profit growth

125.32

-66.95

-25.82

42.48

EBIT growth

-148.19

-133.47

-32

46.22

Net profit growth

-25.41

-208.91

-12.75

51.55

View Ratios

No Record Found

Ahlcon Parenterals India Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,776.15

150.914,20,027.58237.820.774,409.7498.75

Divis Laboratories Ltd

DIVISLAB

4,855.95

78.491,30,370.294300.612,063507.93

Cipla Ltd

CIPLA

1,575

32.241,28,058.811,055.940.823,752.25346.4

Zydus Lifesciences Ltd

ZYDUSLIFE

1,178.65

27.871,21,729.161,700.80.254,035.4156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,953.2

28.241,16,346.951,417.20.575,823.91,458.7

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Ahlcon Parenterals India Ltd

Management

Register Office

Registrar Office

Director

SHIV CHARAN LAL GUPTA

Director

ARUN KUMAR GUPTA

Director

SUNINDER SINGH ARORA

Managing Director

INDRANIL MUKHERJEE

Director

ANDREAS WALDE

Additional Director

CHRISTOPH MUELLER

Company Secretary

RANJAN KUMAR SAHU

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Earlier known as Gujarat Inject, the company was incorporated on 20 Jan.92. It has been promoted by Ahluwalia Contracts and Bikramjit Ahluwalia.It manufactures and markets IV fluids. Intravenous fluid solutions are manufactured both by the organised and unorganised sector. The fluids are packed in aseptic plastic/glass bottles and in pouches manufactured by the unorganised sector. The product mix of various IV fluids manufactured by the company comprises injection dextrose 5%, dextrose saline / normal saline, dextrose 10%, lactate solution and multiple electrolyte solutions. IV fluids besides being injected into patients for post- and pre-operative care, are also used in cases of de-hydration, weakness, etc.IV fluids are generally sold through dealers. The company has tied-up for technical know-how from Gujarat Inject. It came out with a public issue in Jan.94 to part-finance an IV fluid project with an installed capacity of 14 mln bottles pa. Ahlcon, initially set up with an installed capacity of 14 mln bottles pa, was planned further to increase the capacity of 21 mln bottles p.a. The company diversified into opthalmic/ear care products by creating additional capacities of 200 lacs bottles in small volume parentals. It has also carried on a 2nd phase of expansion in both LVP and SVP with a additional capacity of 180 lacs bottles and 480 lacs bottles respectively. The commercial production has already been started.
Read More

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020
  • Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.
  • Pay 20% upfront margin of the transaction value to trade in cash market segment.
  • Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.
  • Check your Securities / MF / Bonds in the consolidated account statement issued by NSDL/CDSL every month.
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp